# OnCo record retlirafusp-alfa (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/retlirafusp-alfa/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "retlirafusp-alfa" ;
  schema:name "Retlirafusp alfa"@en ;
  schema:description "Retlirafusp alfa is Hengrui's PD-L1 and TGF-beta bifunctional antibody, in phase 3 trials with chemotherapy in gastric cancer after the Western class leader bintrafusp alfa failed."@en ;
  schema:url <https://onco.cc/drugs/retlirafusp-alfa/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=SHR-1701> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bifunctional fusion protein (anti-PD-L1 antibody fused to a TGF-beta receptor II trap), intravenous" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:trials <https://onco.cc/trials/nct04950322/>, <https://onco.cc/trials/nct07175220/>, <https://onco.cc/trials/nct05300269/>, <https://onco.cc/trials/nct07102901/>, <https://onco.cc/trials/nct05671822/> .